Edwards Lifesciences Co. (NYSE:EW) VP Donald E. Bobo, Jr. Sells 5,000 Shares of Stock

Edwards Lifesciences Co. (NYSE:EW) VP Donald E. Bobo, Jr. sold 5,000 shares of the stock in a transaction on Tuesday, October 15th. The stock was sold at an average price of $69.51, for a total transaction of $347,550.00. Following the completion of the sale, the vice president now directly owns 46,936 shares of the company’s stock, valued at approximately $3,262,521.36. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Edwards Lifesciences Trading Down 1.0 %

Shares of EW opened at $68.90 on Wednesday. Edwards Lifesciences Co. has a 1-year low of $58.93 and a 1-year high of $96.12. The company has a 50-day moving average of $67.45 and a 200 day moving average of $79.60. The firm has a market capitalization of $41.52 billion, a price-to-earnings ratio of 29.70, a PEG ratio of 2.83 and a beta of 1.13. The company has a debt-to-equity ratio of 0.08, a current ratio of 3.71 and a quick ratio of 2.87.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings data on Wednesday, July 24th. The medical research company reported $0.70 earnings per share for the quarter, beating analysts’ consensus estimates of $0.69 by $0.01. Edwards Lifesciences had a net margin of 24.55% and a return on equity of 22.35%. The company had revenue of $1.63 billion during the quarter, compared to analyst estimates of $1.65 billion. During the same quarter last year, the business posted $0.66 EPS. The firm’s revenue for the quarter was up 6.7% on a year-over-year basis. On average, research analysts expect that Edwards Lifesciences Co. will post 2.71 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on EW. Citigroup reduced their price objective on shares of Edwards Lifesciences from $83.00 to $77.00 and set a “buy” rating for the company in a research note on Tuesday, October 1st. Barclays cut their target price on shares of Edwards Lifesciences from $90.00 to $80.00 and set an “overweight” rating for the company in a research note on Monday, September 9th. Canaccord Genuity Group cut their target price on shares of Edwards Lifesciences from $77.00 to $66.00 and set a “hold” rating for the company in a research note on Monday, October 7th. Royal Bank of Canada cut their target price on shares of Edwards Lifesciences from $85.00 to $75.00 and set an “outperform” rating for the company in a research note on Tuesday, October 8th. Finally, Deutsche Bank Aktiengesellschaft cut their target price on shares of Edwards Lifesciences from $103.00 to $85.00 and set a “buy” rating for the company in a research note on Thursday, July 25th. Seventeen equities research analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Edwards Lifesciences currently has a consensus rating of “Hold” and an average target price of $75.77.

Institutional Investors Weigh In On Edwards Lifesciences

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Crewe Advisors LLC purchased a new position in Edwards Lifesciences during the 1st quarter valued at about $28,000. First Community Trust NA purchased a new position in Edwards Lifesciences during the 2nd quarter valued at about $29,000. Riverview Trust Co purchased a new position in Edwards Lifesciences during the 1st quarter valued at about $34,000. Webster Bank N. A. purchased a new position in Edwards Lifesciences during the 2nd quarter valued at about $39,000. Finally, Peoples Bank KS purchased a new position in Edwards Lifesciences during the 3rd quarter valued at about $40,000. Institutional investors own 79.46% of the company’s stock.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.